Spago’s CEO: Advancing the Tumorad programme comes first

Spago Nanomedical’s Q1 report signals steady progress with its radiopharma pipeline.

Lead programme Tumorad recently got a boost by the release of positive non-clinical data in a triple-negative breast cancer model, incentivising the company to strengthen its management. – 2024 has begun in the same positive spirit as we ended last year.